-The Hindu   As a sun-swept country, India should have been a pioneer in the use of solar power with a photovoltaic panel on every roof. Good policy can help make up for lost time. Solar is the most secure of all energy sources, since it is abundantly available in India. With crippling electricity shortages, the price of electricity traded internally touched Rs. 7 a unit for base loads and Rs. 8.50 during...

-The Economic Times The CBI manual contradicts the government's stance that it did no wrong in vetting the draft status report of the agency's probe in the coal allocation case, say legal experts, former CBI officials and activists. The manual says while CBI's superintendence is vested in the central government, its supervising authority is the Central Vigilance Commission in case of investigation of offences alleged to have been committed under the...

-The Telegraph A parliamentary panel has recommended that the Union government dissolve the ministry of development of north eastern region (DoNER) and put it under the Prime Minister's Office. The reason for the ministry's dissolution has been attributed to the plummeting efficiency levels and achievement rate in its planned schemes. "The committee, therefore, strongly recommends that the government should consider the handicaps of the DoNER ministry in a very serious manner. It should...

-The Hindu Business Line Fresh guidelines issued on procurement details, disclosure of CAG reports Public-private partnerships (PPPs) will soon come under the ambit of the RTI (right to information) as per a fresh set of guidelines issued by the Department of Personnel and Training (DoPT) on April 15. According to the guidelines on suo motu disclosure under Section 4 of RTI Act, 2005, the DoPT says since public services are proposed to be...

-The Times of India JAIPUR: In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) free of cost to them. The government's decision follows the April 1 Supreme Court decision to dismiss Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec (Imatinib). Currently the tablet is sold in the market by Novartis at...